您使用的浏览器不受支持。
本网站的某些功能可能无法正常运行。为获得最佳的用户体验,请使用Chrome、Firefox、Safari或Edge浏览本网站。

领导团队

我们的使命是作为改善全球人类健康的生物药生产领域受信赖的合作伙伴,激励生物工艺发展。我们专注于成本和工艺效率,提供创新的技术和解决方案,帮助制定生物工艺的新标准。

执行官

Tony J. Hunt

总裁,首席执行官


Tony-Hunt-yin-sized.jpgTony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

Repligen CEO Tony Hunt Knows Why Sucess Takes Time

Jon K. Snodgres

首席财务官

Jon-Snodgres-yin-sized.jpgJon K. Snodgres joined Repligen in July 2014 as the Chief Financial Officer, where he oversees financial operations for the Company. Mr. Snodgres was previously with Maquet Cardiovascular (“Maquet”), a medical device company, where he served as Chief Financial Officer for five years. At Maquet, in addition to being responsible for the preparation and oversight of the company’s financial statements, he was a key participant in growth planning and profit improvement strategies. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific in various roles, most recently as Vice President of Finance for the Laboratory Products Group. He began his career in finance at AlliedSignal/Honeywell International. Mr. Snodgres received a B.S. in Business Administration, Finance from Northern Arizona University.

Jim Bylund

Chief Operating Officer

jim_bylund_web (3).jpgJames R. Bylund was named Chief Operating Officer of the Company in January 2022 and serves as the Company’s principal operating officer. He joined Repligen in March of 2020 as Senior Vice President, Global Operations and IT, overseeing all operations and IT functions on a global basis. Between March 2019 and March 2020, Mr. Bylund also worked in real estate at Inspire Development in Austin, Texas. Prior to joining Repligen, Mr. Bylund spent ten years at Thermo Fisher Scientific in a number of roles including Vice President and General Manager of the Single Use Technologies Business Unit and Vice President of Global Operations for the Bioproduction Division. Prior to joining Thermo Fisher, Mr. Bylund also worked for Fiserv (9 years) and Eli Lilly and Company (7 years) in a variety of leadership roles. He has significant experience in managing multiple operating sites across the globe and scaling operations to meet rapidly growing demand. Mr. Bylund is a passionate proponent of continuous improvement and has consistently demonstrated the ability to assemble and grow highly effective teams. He holds a B.S. in Accounting from Utah State University and an M.B.A. from Indiana University.

      

Christine Gebski

Senior Vice President, Filtration and Chromatography


christine-gebski-yin-sized.jpgChristine Gebski joined Repligen in May 2015 and currently serves as the Senior Vice President, Filtration and Chromatography where she oversees the general management and strategy of the Company’s upstream and downstream filtration and chromatography portfolio. Ms. Gebski also manages the Customer Service and Field Applications functions within the Company, ensuring strong customer experience. Prior to joining Repligen, Ms. Gebski was head of the Chromatography Business Unit within the Bioproduction Division of Thermo Fisher Scientific. At Thermo Fisher she managed the Global Process Chromatography Applications and R&D functions for ten years. Before joining Thermo Fisher Scientific, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry having held positions of increasing responsibility at Genzyme, TKT/Shire and EMD Pharmaceuticals. She has significant experience in downstream process development and engineering, technology transfer and validation across a variety of biological molecule classes and diagnostic reagents. She holds a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.

Ralf Kuriyel

高级副总裁,研发

Ralf-Kuriyel-yin-sized.jpgRalf Kuriyel joined Repligen in October 2016 as the Senior Vice President, Research and Development where he oversees the Company’s R&D efforts. Mr. Kuriyel was previously Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation (“Pall”), whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. Mr. Kuriyel received a B.S. and an M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and has completed his coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.

职能部门领导人

Gautam Choudhary

Senior Vice President, Systems and Automation

Gautam_Choudhary2.jpgGautam Choudhary于2018年11月作为生物工艺系统和自动化副总裁和总经理加入Repligen。他负责TFF系统的基础设施建设以及策略开发,并促进用于连续生产的工艺流。加入Repligen之前,Gautam曾在Lonza工作,支持战略和运行项目,并为生物科学解决方案开发了针对细胞和基因治疗的市场推广策略。Lonza之前,他在Life Technologies/Thermo Fisher工作了12年,领导生物生产部门的细胞培养(Gibco)业务。加入Life之前,他在Millipore担任了多个技术和商业职位,支持亚洲和欧洲的过滤、层析及系统业务。Choudhary先生拥有英国利兹大学机械工程学士学位及市场工商管理学硕士学位(MBA)。

Steve Curran

副总裁,全球运营

Steve Curran于2015加入Repligen,此前,他是Life Technologies/Thermo Fisher Scientific 的全球网络领导。steve-curran-yin-sized.jpg 过去10年,Curran先生在全球多地管理全球基因分析和层析耗材业务,通过精益方法学和升级质量系统,建立了高效的业务运营。他还领导了两个符合严格法规要求的多产品生产线的设计、构建和委托制造。在此之前,Curran先生作为研发工程师,在生物技术行业工作了15年,担任了不同级别的领导职务,包括产品转让、工艺规模放大和验证。他于马萨诸塞州的伍斯特理工学院获得化学工程学士学位。

Rachel Goodrich

副总裁,市场

Rachel Goodrich于2017年3月被任命为Repligen市场副总裁,rachel-goodrich-yin-sized.jpg Repligen in January 2015. She rebranded Repligen as a bioprocessing company, developed and launched the Repligen website, implemented high ROI tools from online Marketing-On-Demand to global technical roadshows, building out an organization covering strategic marketing, digital marketing, creative design and marketing communications.  Prior to joining Repligen, she was Market Development Leader for the Bioproduction Division of LIFE Technologies/ Thermo Fisher Scientific/ Applied Biosystems, responsible for global market development and marketing programs for four franchise business units, and was the recipient of numerous Marketing Excellence Awards. She holds a Bachelor's degree in Economics from the University of the Philippines, a Master's Degree in Economics, a Master's Degree in Education and completed all course work for a Ph.D. in Economics from Stanford University.

Vikas Gupta

Vice President and General Manager, Downstream Bioprocessing and Gene Therapy

Vikas Gupta于2016年3月作为业务发展和战略副总裁加入Repligen。Vikas Gupta 加入Repligen之前,Gupta先生曾于2012至2015年在GE生命科学担任商业领导职务,管理其企业解决方案 & 服务业务以及一次性使用和过滤产品线。加入GE之前,Gupta先生于2004至2011年间,在Millipore担任业务开发和产品管理职务,在Mobius一次性使用生物工艺业务早期研发中,发挥了重要作用。他是使用基于风险的方法评估溶出物和析出物影响以及可抛弃型产品处置可持续性的早期倡导者之一。他在印度获得化学工程学士学位和MBA,并在马萨诸塞州沃尔瑟姆的宾利大学获得了金融学硕士学位。

Craig Harrison

Senior Vice President, Analytics

Craig_Harrison.jpgBefore joining Repligen in 2019, Craig Harrison served as the President and Founder of C Technologies, Inc. for over 35 years. Craig and his team worked closely with a wide range of industries to deliver fiber optic assemblies, instrumentation, and systems for spectroscopy applications that were designed and manufactured in-house. In 2008, he launched the SoloVPE® System that uses Slope Spectroscopy® that has become the standard for concentration measurement in the biotech industry. Craig leverages his background in business development and fiber optics in his current role at Repligen, where he focuses on Analytics. He holds a Bachelor’s degree in Economics from the University of Rochester.

Kola Otitoju

Senior Vice President, Strategy and Business Development

Kola_Otitoju_C_20200810_web.jpgKola Otitoju joined Repligen in 2020 as Senior Vice President of Strategy and Business Development. He is responsible for leading the development and execution of the Repligen growth strategy including partnerships, licensing, investments and mergers and acquisitions. Mr. Otitoju brings a wealth of experience in strategic planning and execution having led multiple transactions in excess of $100BN through his tenures in Investment Banking M&A at Credit Suisse and Banc of America Securities (8 years), large publicly traded corporations including Baxter and GE Healthcare (6 years), and private equity-backed companies like Candela Medical with Apax Partners (3 years). He also brings a strong technical background having been an Electrical Engineer earlier in his career. Mr. Otitoju has Masters Degrees in Business Administration from Harvard Business School and Electrical Engineering from Cornell University, in addition to a Bachelor's Degree in Information Systems Engineering from Imperial College London.

Gustav Silfversparre

Vice President, Operations - Europe

Gustav Silfversparre于2013年3月被任命为Repligen的运营副总裁,管理Repligen位于瑞士隆德的生产基地。Gustav Silfversparre 2013 and is managing Repligen manufacturing sites in Europe. Before coming to Repligen, Mr. Silfversparre was Operations Director at Novozymes Biopharma AB, which was acquired by Repligen in December 2011. Between 2008-2010, Mr. Silfversparre was Head of Biopharma Coordination, a global project and production coordination function for the biopharma area within Novozymes.From 2002 to 2008, Mr. Silfversparre was Head of the Development Department at Novozymes Biopharma AB. Mr. Silfversparre received a Tech. Lic. Biotechnology at Royal Institute of Technology and M.Sc. Chemical Engineering at the Faculty of Engineering, Lund University. 

Stephen Tingley

Vice President, Global Sales

Stephen Tingley毕业于英国利兹大学,已为生物工艺行业贡献超25年。Stephen Tingley Tingley先生最初在GSK工作,之后加入Millipore,创立并分享无菌和下游工艺的专业知识。在Millipore,Tingley先生是公认的一次性使用技术开发和采用的早期倡导者。他拥有多个领先技术商业化的经验,包括用于上游工艺开发的大型平行化微型生物反应器系统、多柱层析以及最近领导Repligen的可抛弃型层析团队,开发了OPUS® 预装柱产品线。 

董事会

全部展开

Karen-Dawes.jpg

Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC (“Wyeth”), a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves on the board of directors of two publicly traded companies: Vaccitech plc and Medicenna Therapeutics Corp, one private company, PaxMedica, Inc., and on one not-for-profit company, Medicines 360.
Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.

Nicolas Barthelemy.jpgNicolas M. Barthelemy has served as a director of Repligen since June 2014. Mr. Barthelemy brings over 30 years of industry experience to the director role. Mr. Barthelemy served as President and CEO of bioTheranostics, a molecular diagnostics company, from September 2014 until February 2017. Prior to bioTheranostics, he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen Inc. (“Biogen”) for eight years, most recently as Vice President, Manufacturing and General Manager for the company’s manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. Mr. Barthelemy also serves on the board of directors of three publicly traded companies: Fluidigm Corporation, Twist Bioscience and 908 Devices Inc., and three privately held companies; Biocare Medical LLC, NanoCellect Biomedical, and Slingshot Biosciences. He also serves as an advisor to Warburg Pincus, a private equity firm. Mr. Barthelemy received an M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles, Paris. Mr. Barthelemy’s qualifications to sit on the Company’s Board include his extensive experience in the bioprocessing field, including large scale biologics manufacturing and commercialization of consumables used in bioprocessing.

Tony-square.jpgTony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

Konstantin Konstantinov, Ph.D., has served as a director of Repligen since May 2022. He is also a member of our Scientific Advisory Board since March 2016. Dr. Konstantinov is currently Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.

carrie_ellington_manner.jpgCarrie Eglinton Manner has served as a director of Repligen since June 2020. She brings to the director role over 25 years of leadership experience across multiple disciplines. Ms. Eglinton Manner currently serves as Senior Vice President, Advanced & General Diagnostics and Clinical Solutions at Quest Diagnostics (“Quest”), which she joined in 2017. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab
services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. In her role at Quest, Ms. Eglinton Manner is responsible for value creation across the company’s $10 billion clinical portfolio, driving innovation in R&D, along with partnerships and acquisitions. She has helped accelerate growth in Quest’s $2 billion Advanced Diagnostics portfolio, which includes its specialty molecular and genetic offerings, along with Quest’s global and pharmaceutical services businesses. She also serves as Executive Sponsor for Quest’s African-American Business Leaders Network. In addition to the Repligen Board, Ms. Eglinton Manner serves as board director for the not-for-profit Thrive Networks, focused on advancing women and transforming health in underserved communities in Southeast Asia. Ms. Eglinton Manner holds a B.S. in Mechanical Engineering from the University of Notre Dame. Ms. Eglinton Manner’s qualifications to sit on the Company’s Board include her track record of delivering business expansion and profitability for rapidly growing global businesses, including her experience with integrating acquisitions and building operations excellence, with a commitment to quality and process improvements.

Rohin-Mhatre-picture.pngRohin Mhatre, Ph.D., was appointed to the Board in March 2020. Dr. Mhatre brings over 25 years of relevant experience to the director role, including his current position since January 2017, as Senior Vice President, Product and Technology Development at Biogen. He has held numerous other roles of increasing responsibility within Biogen, which he joined in 1996, including six years as Vice President of Biopharmaceutical Development, where he led a 300-member team responsible for cell line, cell culture,
purification and device development. Earlier in Dr. Mhatre’s career at Biogen, he focused on building out analytical development and technical services. Prior to Biogen, Dr. Mhatre led the purification and applications group at Applied BioSystems (formerly Perspective Biosystems). Dr. Mhatre holds a Ph.D. in Chemistry from Northeastern University. Dr. Mhatre’s qualifications to sit on the Company’s Board include his extensive technical expertise, his leadership abilities and his deep understanding of the dependencies between biological drug development and efficient manufacturing workflows.

Glenn_Muir.jpgGlenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc. (“Hologic”), a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President. Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venture-backed single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984, he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir also serves on the board of directors of two publicly traded companies: medical technology company, Neuronetics, Inc., and life science company G1 Therapeutics, Inc., and one privately held company: medical device company Impulse Dynamics Limited. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S. from Bentley University and an M.B.A. from Harvard University. Mr. Muir’s qualifications to sit on Repligen’s Board include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization.

科学顾问委员会

全部展开

Richard D. Braatz是麻省理工学院(MIT)的Edwin R. Gilliland教授,他在工艺数据分析、设计和先进制造系统的控制方面进行研究。他拥有加利福尼亚理工学院硕士学位和博士学位,曾是伊利诺伊大学厄本那-香槟分校的千年主席和教授,在加入麻省理工学院之前,他是哈佛大学的访问学者。他已经与超过30家公司进行了咨询和/或合作,其中包括默克、诺华、辉瑞、安进、百健和百时美施贵宝。他是美国国家工程院院士。

Charles L. Cooney是麻省理工学院化学工程系荣誉退休教授罗伯特·哈斯拉姆(1911)化学和生化工程教授,也是麻省理工学院Deshpande技术创新中心荣誉退休教授。他拥有宾夕法尼亚大学化学工程学士学位以及麻省理工学院的生物化学工程硕士和博士学位。他曾在麻省理工学院任教。他是工艺设计、上游和下游生物工艺开发以及制药和生物制品生产方面的专家。Cooney教授曾担任多家生物技术和制药公司的顾问或董事会成员,并且是Repligen科学顾问委员会主席。

Cramer博士是伦斯勒理工学院的William Weightman Walker教授,并以其对复杂生物制品的分离以及层析材料、工艺和可用于其生物制造的预测工具的开发所做出的贡献而闻名。此外,他对分子间相互作用的理解做出了开创性的贡献,这些相互作用在这些分离系统中产生了独特的选择性。他的实验室目前正在与蛋白质-表面相互作用相关的几个领域进行研究,包括蛋白质结合亲和性的预测和层析系统的多维度建模、高效抗体和双特异性抗体分离系统的开发、多峰色谱的基础研究、多级自动肽合成/筛选亲和肽设计系统、智能生物聚合物亲和沉淀系统、蛋白质与表面、配体和蛋白质相互作用的生物物理学、有效去除工艺HCP的平台化策略以及集成的半连续生物生产工艺。他已担任《分离科学与技术》的编辑20年,曾获得Alan S. Michaels生物制品回收奖(生化技术ACS部)和ACS国家分离科学与技术奖。他还获得了伦斯勒杰出教授奖以及工程学院杰出教授和卓越研究奖。Cramer博士当选为美国科学促进协会、美国化学工程师学会、美国化学学会和美国医学与生物工程学会的研究员。 

Alfred Goldberg is a Professor of Cell Biology at Harvard Medical School. His research has concerned the mechanisms and regulation of protein breakdown in cells. His laboratory first demonstrated the existence of the non-lysosomal pathway for protein breakdown (now termed the ubiquitin-proteasome pathway), the 26S proteasome, and the ATP-dependent proteases responsible for protein degradation in bacteria. He also initiated the development of the proteasome inhibitor, Bortezomib/Velcade, now used worldwide for the treatment of multiple myeloma. His research accomplishments have been recognized with many honors, including three honorary degrees, the Gordon Alpert Prize, the Ernst Beutler Prize, and the 2021 Passano Award for Medical Research. He has been elected to the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts & Sciences, and he is among the 0.01% most cited authors in the life sciences. Dr. Goldberg has served frequently as a consultant to biotech companies and for 7 years served on the Board of Directors of Repligen. 

Konstantin Konstantinov, Ph.D., has been a member of our Scientific Advisory Board since March 2016. He also serves as a director of Repligen since May 2022. Dr. Konstantinov is currently Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.

J. Christopher Love是Raymond A.(1921)和Helen E. St. Laurent化学工程教授,也是麻省理工学院科赫综合癌症研究所的成员。此外,他还是Eli和Edythe L. Broad研究所以及MGH Ragon研究所、MIT和哈佛的准成员。Love教授于2004年获得哈佛大学物理化学博士学位。他于2004年-2005年在哈佛医学院及2005年-2007年在免疫疾病研究所将其研究扩展到了免疫学领域。他的研究集中在使用简单的微系统来监测慢性人类疾病临床样本中的细胞,以及开发新方法,用于生产高效且负担得起的生物药和疫苗。Love教授在2009年被评为Dana人类免疫学学者,并被授予Keck杰出青年医学研究学者,在2010年被评为科普杰出人才10之一,并被Camille Dreyfus授予教师奖学金。在麻省理工学院,他是替代宿主协会主席,其是麻省理工学院与工业界独特的合作,致力于推动生物制药和疫苗的新生产宿主的发展。他之前曾在Biogen(2015-2016)担任驻地杰出工程师,还为多家生物技术和生物制药公司提供咨询服务,包括三家基于他在麻省理工学院实验室所开发的技术的初创公司(Honeycomb、OneCyte和Sunflower)。